NCT00174343已完成2 期
Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 46
- 试验地点
- 6
- 主要终点
- To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
研究概览
简要总结
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive
排除标准
- •Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative
结局指标
主要结局
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
次要结局
- To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerBreast CancerNCT00201864Ohio State University Comprehensive Cancer Center40
已完成
1 期
2-Methoxyestradiol in Treating Patients With Advanced Solid TumorsRefractory Multiple MyelomaStage III Multiple MyelomaUnspecified Adult Solid Tumor, Protocol SpecificNCT00028821National Cancer Institute (NCI)60
已完成
2 期
Exemestane in Post-Menopausal Women With NSCLCNon-Small Cell Lung CancerNCT02666105Masonic Cancer Center, University of Minnesota6
终止
2 期
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine TherapyCancer of the BreastNeoplasms, BreastBreast CancerNCT00661531Georgetown University11
已完成
2 期
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerStage 0 Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7NCT02598557National Cancer Institute (NCI)180